Medical Properties Trust Inc's income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Dec 31, 2025 · FY), Medical Properties Trust Inc reported revenue of $972.0M (-2.4% year on year) and net income of ($277.0M) (+88.5% year on year).
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Rent billed | $736.5M | $719.7M | $803.4M | $968.9M |
| Straight-line rent | $152.2M | $163.4M | ($127.9M) | $204.2M |
| Income from financing leases | $39.7M | $63.7M | $127.1M | $203.6M |
| Interest and other income | $43.6M | $48.7M | $69.2M | $166.2M |
| Total revenues | $972.0M | $995.5M | $871.8M | $1.5B |
| Interest | $510.4M | $417.8M | $411.2M | $359.0M |
| Real estate depreciation and amortization | $265.4M | $447.7M | $603.4M | $333.0M |
| Property-related | $36.4M | $27.3M | $41.6M | $45.7M |
| General and administrative | $130.4M | $133.8M | $145.6M | $160.5M |
| Total expenses | $942.6M | $1.0B | $1.2B | $898.2M |
| Gain (loss) on sale of real estate | $5.5M | $478.7M | ($1.8M) | $536.8M |
| Real estate and other impairment charges, net | ($193.9M) | ($1.8B) | ($376.9M) | ($268.4M) |
| Earnings (loss) from equity interests | $97.9M | ($366.6M) | $14.0M | $40.8M |
| Debt refinancing and unutilized financing (costs) benefit | ($3.6M) | ($4.3M) | — | — |
| Other (including fair value adjustments on securities) | ($172.6M) | ($615.6M) | $7.6M | $15.3M |
| Total other expense | ($266.7M) | ($2.3B) | ($356.9M) | $315.1M |
| Loss before income tax | ($237.3M) | ($2.4B) | ($686.8M) | $959.7M |
| Income tax (expense) benefit | ($38.6M) | ($44.1M) | $130.7M | ($55.9M) |
| Net (loss) income | ($275.9M) | ($2.4B) | ($556.1M) | $903.8M |
| Net income attributable to non-controlling interests | ($1.1M) | ($2.0M) | ($384.0K) | ($1.2M) |
| Net loss attributable to MPT common stockholders | ($277.0M) | ($2.4B) | ($556.5M) | $902.6M |
| Net loss attributable to MPT common stockholders (Operating Partnership partners), basic | -$0.46 | -$4.02 | -$0.93 | $1.50 |
| Net loss attributable to MPT common stockholders (Operating Partnership partners), diluted | -$0.46 | -$4.02 | -$0.93 | $1.50 |
| Weighted average shares (units) outstanding basic | 600.9M | 600.2M | 598.5M | 598.6M |
| Weighted average shares (units) outstanding diluted | 600.9M | 600.2M | 598.5M | 598.8M |
| Line item | Jun 30, 2026 · Q2 | Mar 31, 2026 · Q1 | Sep 30, 2025 · Q3 | Jun 30, 2025 · Q2 |
|---|---|---|---|---|
| Rent billed | $203.4M | $197.5M | $181.0M | $177.9M |
| Straight-line rent | $33.3M | $34.2M | $36.4M | $39.7M |
| Income from financing leases | $10.1M | $10.1M | $9.9M | $9.9M |
| Interest and other income | $12.5M | $10.3M | $10.2M | $12.9M |
| Total revenues | $259.3M | $252.1M | $237.5M | $240.4M |
| Interest | $135.3M | $133.3M | $132.4M | $129.7M |
| Real estate depreciation and amortization | $69.5M | $69.7M | $67.0M | $66.7M |
| Property-related | $11.2M | $9.9M | $9.0M | $10.9M |
| General and administrative | $34.8M | $32.2M | $37.7M | $26.2M |
| Total expenses | $250.7M | $245.2M | $246.1M | $233.5M |
| Gain on sale of real estate | $6.5M | ($790.0K) | ($9.1M) | $5.2M |
| Real estate and other impairment charges, net | ($16.8M) | ($19.0M) | ($81.8M) | ($1.4M) |
| Earnings from equity interests | $11.4M | $15.7M | $34.4M | $25.3M |
| Debt refinancing and unutilized financing benefit (costs) | $0 | $0 | — | $181.0K |
| Other (including fair value adjustments on securities) | ($1.9M) | ($2.5M) | ($1.5M) | ($124.4M) |
| Total other expense | ($806.0K) | ($6.6M) | ($58.0M) | ($95.1M) |
| Income (loss) before income tax | $7.8M | $285.0K | ($66.6M) | ($88.3M) |
| Income tax benefit (expense) | ($10.1M) | $32.8M | ($10.9M) | ($9.8M) |
| Net income (loss) | ($2.3M) | $33.1M | ($77.5M) | ($98.1M) |
| Net income attributable to non-controlling interests | ($307.0K) | ($280.0K) | ($280.0K) | ($289.0K) |
| Net income (loss) attributable to MPT common stockholders | ($2.6M) | $32.8M | ($77.7M) | ($98.4M) |
| Net income (loss) attributable to MPT common stockholders (Operating Partnership partners), basic | -$0.01 | $0.05 | -$0.13 | -$0.16 |
| Net income (loss) attributable to MPT common stockholders (Operating Partnership partners), diluted | -$0.01 | $0.05 | -$0.13 | -$0.16 |
| Weighted average shares (units) outstanding basic | 598.0M | 597.7M | 601.1M | 600.8M |
| Weighted average shares (units) outstanding diluted | 598.0M | 597.7M | 601.1M | 600.8M |
| Dividends declared per common share (unit) | $0.09 | $0.09 | $0.08 | $0.08 |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Land | $1.8B | $1.6B | $1.8B | $1.9B |
| Buildings and improvements | $9.5B | $8.8B | $10.4B | $10.4B |
| Intangible lease assets | $872.4M | $804.1M | $1.0B | $1.4B |
| Investment in financing leases | $421.7M | $1.1B | $1.2B | $1.7B |
| Real estate held for sale | $0 | $34.0M | — | $0 |
| Mortgage loans | $123.7M | $119.9M | $309.3M | $364.1M |
| Gross investment in real estate assets | $12.8B | $12.5B | $14.8B | $15.9B |
| Accumulated depreciation | ($1.4B) | ($1.2B) | ($1.2B) | ($1.0B) |
| Accumulated amortization | ($224.5M) | ($201.3M) | ($180.4M) | ($185.0M) |
| Net investment in real estate assets | $11.1B | $11.0B | $13.4B | $14.7B |
| Cash and cash equivalents | $540.9M | $332.3M | $250.0M | $235.7M |
| Interest and rent receivables | $19.2M | $36.3M | $45.1M | $167.0M |
| Straight-line rent receivables | $881.5M | $700.8M | $636.0M | $787.2M |
| Investments in unconsolidated real estate joint ventures | $1.4B | $1.2B | $1.5B | $1.5B |
| Investments in unconsolidated operating entities | $322.2M | $439.6M | $1.8B | $1.4B |
| Other loans | $186.3M | $109.2M | $292.6M | $227.8M |
| Other assets | $564.0M | $471.4M | $457.9M | $573.0M |
| Total Assets | $15.0B | $14.3B | $18.3B | $19.7B |
| Debt, net | $9.7B | $8.8B | $10.1B | $10.3B |
| Accounts payable and accrued expenses | $549.1M | $454.2M | $412.2M | $621.3M |
| Deferred revenue | $19.3M | $29.4M | $38.0M | $27.7M |
| Obligations to tenants and other lease liabilities | $128.3M | $129.0M | $156.6M | $146.1M |
| Payable due to Medical Properties Trust, Inc. | $55.4M | $48.2M | $92.8M | $176.6M |
| Total Liabilities | $10.4B | $9.5B | $10.7B | $11.1B |
| Common stock, $0.001 par value. Authorized 750,000 shares; issued and outstanding - 597,008 shares at December 31, 2025 and 600,403 shares at December 31, 2024 | 597.0K | 600.0K | 599.0K | 597.0K |
| General Partner - issued and outstanding - 5,972 units at December 31, 2025 and 6,006 units at December 31, 2024 | $44.5M | $49.3M | $76.0M | $86.6M |
| Limited Partners - issued and outstanding - 591,036 units at December 31, 2025 and 594,397 units at December 31, 2024 | $4.4B | $4.9B | $7.5B | $8.6B |
| Additional paid-in capital | $8.6B | $8.6B | $8.6B | $8.5B |
| Retained deficit | ($4.1B) | ($3.7B) | ($971.8M) | $116.3M |
| Accumulated other comprehensive income (loss) | $168.2M | ($94.3M) | $42.5M | ($59.2M) |
| Total Medical Properties Trust, Inc. Stockholders' Equity (MPT Operating Partnership, L.P. capital) | $4.6B | $4.8B | $7.6B | $8.6B |
| Non-controlling interests | $1.1M | $1.1M | $2.3M | $1.6M |
| Total Equity / Capital | $4.6B | $4.8B | $7.6B | $8.6B |
| Total Liabilities and Equity / Capital | $15.0B | $14.3B | $18.3B | $19.7B |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Sep 30, 2025 | Jun 30, 2025 |
|---|---|---|---|---|
| Land, buildings and improvements, intangible lease assets, and other | $12.1B | $12.1B | $11.7B | $11.9B |
| Investment in financing leases | $383.0M | $381.6M | $943.8M | $1.0B |
| Mortgage loans | $131.2M | $124.5M | $127.9M | $123.9M |
| Gross investment in real estate assets | $12.7B | $12.6B | $12.8B | $13.0B |
| Accumulated depreciation and amortization | ($1.7B) | ($1.7B) | ($1.6B) | ($1.6B) |
| Net investment in real estate assets | $10.9B | $10.9B | $11.2B | $11.4B |
| Cash and cash equivalents | $396.6M | $425.0M | $396.6M | $509.8M |
| Interest and rent receivables | $18.4M | $18.0M | $25.1M | $28.6M |
| Straight-line rent receivables | $927.5M | $904.1M | $851.7M | $825.8M |
| Investments in unconsolidated real estate joint ventures | $1.4B | $1.4B | $1.4B | $1.4B |
| Investments in unconsolidated operating entities | $313.7M | $320.9M | $319.2M | $323.4M |
| Other loans | $286.5M | $238.0M | $245.5M | $149.0M |
| Other assets | $519.1M | $563.8M | $519.3M | $513.6M |
| Total Assets | $14.7B | $14.8B | $14.9B | $15.2B |
| Debt, net | $9.7B | $9.7B | $9.6B | $9.6B |
| Accounts payable and accrued expenses | $430.1M | $433.2M | $475.9M | $494.8M |
| Deferred revenue | $17.1M | $18.6M | $22.1M | $23.5M |
| Obligations to tenants and other lease liabilities | $95.7M | $102.5M | $148.6M | $149.3M |
| Payable due to Medical Properties Trust, Inc. | $54.2M | $54.3M | $48.4M | $48.3M |
| Total Liabilities | $10.2B | $10.2B | $10.3B | $10.3B |
| Common stock, $0.001 par value. Authorized 750,000 shares; issued and outstanding - 597,715 shares at June 30, 2026 and 597,008 shares at December 31, 2025 | 597.0K | 598.0K | 601.0K | 601.0K |
| General Partner - issued and outstanding - 5,970 units at June 30, 2026 and 5,972 units at December 31, 2025 | $43.7M | $44.3M | $45.1M | $46.3M |
| Limited Partners - issued and outstanding - 590,816 units at June 30, 2026 and 591,036 units at December 31, 2025 | $4.3B | $4.4B | $4.5B | $4.6B |
| Additional paid-in capital | $8.6B | $8.6B | $8.6B | $8.6B |
| Retained deficit | ($4.2B) | ($4.2B) | ($4.1B) | ($4.0B) |
| Accumulated other comprehensive income | $135.0M | $123.7M | $154.7M | $205.8M |
| Total Medical Properties Trust, Inc. Stockholders' Equity (MPT Operating Partnership, L.P. capital) | $4.5B | $4.5B | $4.7B | $4.8B |
| Non-controlling interests | $1.1M | $1.1M | $1.1M | $1.1M |
| Total Equity / Capital | $4.5B | $4.5B | $4.7B | $4.8B |
| Total Liabilities and Equity / Capital | $14.7B | $14.8B | $14.9B | $15.2B |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Net loss | ($275.9M) | ($2.4B) | ($556.1M) | $903.8M |
| Depreciation and amortization | $272.8M | $453.7M | $616.1M | $345.6M |
| Amortization of deferred financing costs and debt discount | $26.3M | $17.3M | $15.8M | $17.0M |
| Straight-line rent revenue and other | ($158.2M) | ($172.8M) | ($233.7M) | ($282.5M) |
| Stock / (Unit)-based compensation expense | $25.7M | $33.0M | $33.3M | $49.4M |
| (Gain) loss on sale of real estate | ($5.5M) | ($478.7M) | $1.8M | ($536.8M) |
| Real estate and other impairment charges, net | $193.9M | $1.8B | $376.9M | — |
| Straight-line rent and other write-off | $11.1M | $2.5M | $649.9M | — |
| Debt refinancing and unutilized financing (benefit) costs | $3.6M | $4.3M | ($285.0K) | — |
| Tax rate changes and other | ($11.2M) | $5.1M | ($167.3M) | — |
| Non-cash fair value adjustments | $106.4M | $563.7M | — | — |
| Other adjustments | $7.6M | $5.0M | ($23.9M) | $6.1M |
| Interest and rent receivables | $7.1M | $2.8M | ($141.7M) | ($116.4M) |
| Other assets | $15.0M | ($36.1M) | $13.8M | ($4.0M) |
| Accounts payable and accrued expenses | $21.7M | $23.5M | ($4.6M) | $33.6M |
| Deferred revenue | ($9.6M) | ($5.8M) | $7.6M | $43.0K |
| Net cash provided by operating activities | $230.8M | $245.5M | $505.8M | $739.0M |
| Cash paid for acquisitions and other related investments | ($142.1M) | ($105.6M) | ($235.2M) | ($1.3B) |
| Net proceeds from sale of real estate | $120.5M | $1.9B | $897.5M | $2.2B |
| Principal received from sale and repayment of loans receivable | $116.3M | $214.4M | — | — |
| Investment in loans receivable | ($205.8M) | ($420.3M) | ($250.2M) | ($207.5M) |
| Construction in progress and other | ($80.0M) | ($79.8M) | ($114.4M) | ($109.2M) |
| Capital additions and other investments, net | ($73.8M) | ($156.1M) | ($294.2M) | ($207.4M) |
| Net cash (used for) provided by investing activities | ($264.7M) | $1.3B | $517.6M | $396.1M |
| Proceeds from term debt | $2.5B | $804.2M | — | $128.5M |
| Payments of term debt | ($2.3B) | ($701.8M) | ($988.2M) | ($869.6M) |
| Revolving credit facilities, net | $241.5M | ($1.1B) | $567.9M | $203.6M |
| Dividends / Distribution paid | ($193.3M) | ($321.1M) | ($615.4M) | ($698.5M) |
| Lease deposits and other obligations to tenants | ($3.2M) | $2.2M | $10.1M | ($5.0M) |
| Offering costs | ($727.0K) | — | — | — |
| Repurchase of common stock / unit | ($23.4M) | — | — | ($17.9M) |
| Stock / Unit vesting - satisfaction of tax withholdings | ($2.5M) | ($3.8M) | ($8.1M) | ($29.9M) |
| Payment of debt refinancing and deferred financing costs and other financing activities | ($50.6M) | ($127.8M) | $13.3M | ($53.6M) |
| Net cash provided by (used for) financing activities | $228.1M | ($1.5B) | ($1.0B) | ($1.3B) |
| Increase in cash, cash equivalents, and restricted cash for the year | $194.1M | $84.4M | $3.0M | ($207.5M) |
| Effect of exchange rate changes | $14.7M | ($5.2M) | $11.4M | ($12.9M) |
| Cash, cash equivalents, and restricted cash at beginning of year | $335.2M | $256.0M | $241.5M | $461.9M |
| Interest paid, including capitalized interest of $12,920 in 2025, $7,642 in 2024, and $14,178 in 2023 | $458.2M | $420.3M | $406.1M | $353.8M |
| Certain obligations and receivable satisfied and real estate sold | $50.0M | — | $722.8M | — |
| Lease incentive provided | $50.0M | — | — | — |
| Dividends declared, unpaid | $55.4M | $48.2M | $92.8M | $176.6M |
| Cash and cash equivalents at beginning of period | $332.3M | $250.0M | $235.7M | $459.2M |
| Restricted cash, included in Other assets at beginning of period | $2.8M | $5.9M | $5.9M | $2.7M |
| Cash, cash equivalents, and restricted cash at beginning of year | $544.0M | $335.2M | $256.0M | $241.5M |
| Cash and cash equivalents at end of period | $540.9M | $332.3M | $250.0M | $235.7M |
| Line item | Jun 30, 2026 · YTD | Mar 31, 2026 · Q1 | Sep 30, 2025 · YTD | Jun 30, 2025 · YTD |
|---|---|---|---|---|
| Net income (loss) | $30.8M | $33.1M | ($293.5M) | ($216.1M) |
| Depreciation and amortization | $147.0M | $73.3M | $203.1M | $133.7M |
| Amortization of deferred financing costs and debt discount | $13.5M | $7.0M | $19.4M | $12.5M |
| Straight-line rent revenue from operating and finance leases | ($70.3M) | ($35.6M) | ($120.7M) | ($82.8M) |
| Straight-line rent revenue and other | ($70.3M) | ($35.6M) | ($120.7M) | ($82.8M) |
| Stock / Unit-based compensation expense | $5.4M | $573.0K | $30.9M | $18.5M |
| Gain on sale of real estate | ($5.7M) | $790.0K | ($4.2M) | ($13.3M) |
| Real estate and other impairment charges, net | $36.4M | $19.5M | $167.1M | $81.5M |
| Debt refinancing and unutilized financing costs | $0 | $0 | $3.6M | $3.6M |
| Tax rate changes and other | ($45.2M) | ($45.2M) | ($11.0M) | $1.1M |
| Non-cash fair value adjustments | $5.5M | ($5.6M) | $123.4M | $135.4M |
| Other adjustments | ($9.3M) | ($1.6M) | ($9.7M) | ($5.3M) |
| Interest and rent receivables | $711.0K | $905.0K | $8.3M | $4.6M |
| Other assets | ($2.3M) | $556.0K | $6.8M | ($3.3M) |
| Accounts payable and accrued expenses | ($56.7M) | ($61.8M) | ($45.7M) | ($11.9M) |
| Deferred revenue | ($1.8M) | ($321.0K) | ($7.1M) | ($6.2M) |
| Net cash provided by operating activities | $48.2M | ($14.3M) | $70.7M | $52.1M |
| Cash paid for acquisitions and other related investments | ($29.3M) | ($29.3M) | ($110.1M) | ($102.3M) |
| Net proceeds from sale of real estate | $18.9M | $18.5M | $97.0M | $47.9M |
| Proceeds received from repayment of loans receivable | $62.9M | $48.7M | — | — |
| Investment in loans receivable | ($146.0M) | ($71.0M) | ($159.0M) | ($52.4M) |
| Construction in progress and other | ($20.2M) | ($12.7M) | ($60.7M) | ($40.6M) |
| Capital additions and other investments, net | ($45.4M) | ($30.9M) | ($34.1M) | ($17.3M) |
| Net cash used for investing activities | ($159.1M) | ($76.8M) | ($256.9M) | ($161.7M) |
| Proceeds from term debt | $0 | $0 | $2.5B | $2.5B |
| Payments of term debt | $0 | $0 | ($2.3B) | ($2.3B) |
| Revolving credit facility, net | $85.0M | $30.0M | $171.5M | $156.5M |
| Dividends / Distribution paid | ($109.6M) | ($55.4M) | ($144.8M) | ($96.5M) |
| Lease deposits and other obligations to tenants | $3.9M | $4.4M | $2.5M | $2.0M |
| Offering costs | ($176.0K) | ($39.0K) | ($644.0K) | ($101.0K) |
| Stock / Unit vesting - satisfaction of tax withholdings | ($2.8M) | ($1.8M) | ($1.5M) | ($745.0K) |
| Repurchase of common stock / unit | ($6.1M) | — | — | — |
| Payment of debt refinancing and deferred financing costs and other financing activities | ($1.8M) | ($456.0K) | ($50.2M) | ($49.8M) |
| Net cash (used for) provided by financing activities | ($31.5M) | ($23.2M) | $237.1M | $271.5M |
| (Decrease) increase in cash, cash equivalents, and restricted cash for period | ($142.4M) | ($114.3M) | $50.9M | $161.9M |
| Effect of exchange rate changes | ($2.1M) | ($1.8M) | $13.6M | $15.8M |
| Interest paid | $279.5M | $174.1M | $393.1M | $220.3M |
| Real estate and other assets provided in property exchange | $158.7M | — | — | — |
| Real estate acquired in property exchange | $165.5M | — | — | — |
| Dividends / Distributions declared, unpaid | $54.2M | $54.3M | $48.4M | $48.3M |
| Cash and cash equivalents at beginning of period | $540.9M | $540.9M | $332.3M | $332.3M |
| Restricted cash, included in Other assets at beginning of period | $3.1M | $3.1M | $2.8M | $2.8M |
| Cash, cash equivalents, and restricted cash at beginning of period | $544.0M | $544.0M | $335.2M | $335.2M |
| Cash and cash equivalents at end of period | $396.6M | $425.0M | $396.6M | $509.8M |
| Restricted cash, included in Other assets at end of period | $2.9M | $3.0M | $3.1M | $3.1M |
Medical Properties Trust Inc score and earnings-call analysis · All covered companies
Figures as reported in SEC filings. General information, not investment advice.